Mineralys Therapeutics Funding & Investors
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
mineralystx.comTotal Amount Raised: $278,000,000
Mineralys Therapeutics Funding Rounds
Post Ipo Equity
$120,000,000
Post Ipo Equity Investors
TCG Crossover ManagementRa Capital ManagementSamsara BioCapitalOrbiMed AdvisorsVenrock Healthcare Capital PartnersSeries B
$118,000,000
Series B Investors
Andera PartnersRa Capital ManagementSectoral Asset ManagementRock Springs CapitalRTW InvestmentsYsios CapitalAdams Street PartnersHealthCor PartnersSamsara BioCapitalSr OneHBM Healthcare InvestmentsCatalys PacificBoulder VenturesSeries A
$40,000,000
Series A Investors
HBM Healthcare InvestmentsSamsara BioCapitalCatalys PacificAdams Street Partners
Funding info provided by Diffbot.